Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

- Data for masked anti-CTLA-4 SAFEbody® ADG126 highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable colorectal cancer with higher, more...

Related Keywords

Germany ,Australia ,Suzhou ,Jiangsu ,China ,Singapore ,Japan ,United States ,German ,American ,Peter Luo ,Zhu Li ,Raymond Tam ,Adagene Safebody ,Asia Pacific ,Ulf Grawunder ,Mervyn Turner ,Yan Li ,Andy Yiu Leung Cheung ,Linkedin ,Audit Committee ,Compensation Committee ,Dynamic Precision Library ,Corporate Governance Committee ,Adagene Inc ,Nasdaq ,Strategy Committee Of The Board ,Exchange Commission ,Information Technology ,Merck Co Inc ,European Union ,American Society Of Clinical Oncology ,Development Rd Expenses ,China Center ,Twitter ,Compensation Committee Of The Board ,Merck Sharp Dohme ,Clinical Oncology ,These Part ,Drug Evaluation ,Strategy Committee ,Yiu Leung ,Man Kin ,Senior Vice President ,Project Optimus ,Operating Income ,Shares Outstanding ,Metastatic Microsatellite Stable ,Colorectal Cancer ,Merck Sharp ,Media Contact ,Consolidated Statements ,Year Ended December ,Markets ,